You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美股異動 | 默沙東跌1% 歐盟藥品監管機構拒絕推薦批准默沙東抗新冠口服藥利卓瑞
格隆匯 02-25 00:34
格隆匯2月25日丨默沙東(MRK.US)跌1.88%,報109.39美元,總市值2773億美元。默沙東與生物技術公司Ridgeback當地時間2月24日發佈聲明稱,歐洲藥品管理局人用藥品委員會(CHMP)對抗新冠病毒口服藥利卓瑞(Lagevrio,莫諾拉韋)的上市授權申請持消極意見。這一意見可能阻止利卓瑞在歐盟銷售。該機構認為,提交的數據不足以證明利卓瑞能夠降低成人新冠患者住院或死亡的風險,或縮短有嚴重疾病風險的成年人的病程。默沙東與Ridgeback計劃對這一決定提出上訴,並要求再次審核CHMP的意見。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account